A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO FOR THE TREATMENT OF ANEMIA DUE TO IPSS-R VERYLOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS WHO REQUIRE RED BLOOD CELL TRANSFUSIONS
Anemia due to Myelodysplastic syndromes (MDS) using study drug luspatercept
Sponsor: Celgene
Enrolling: Male and Female Patients
IRB Number: AAAQ6463
U.S. Govt. ID: NCT02631070
Contact: Joseph Jurcic: 646-317-5077 / jgj2110@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to see if people with certain types of anemia due to MDS will experience a decreased need for regular blood transfusions if they take luspatercept plus best supportive care. The safety of luspatercept will be also evaluated in this study.
This study is closed
Investigator
Joseph Jurcic, MD
Do You Qualify?
Have you been diagnosed with MDS? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Joseph Jurcic
jgj2110@cumc.columbia.edu
646-317-5077
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE